ZA200302722B - Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents. - Google Patents
Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents. Download PDFInfo
- Publication number
- ZA200302722B ZA200302722B ZA200302722A ZA200302722A ZA200302722B ZA 200302722 B ZA200302722 B ZA 200302722B ZA 200302722 A ZA200302722 A ZA 200302722A ZA 200302722 A ZA200302722 A ZA 200302722A ZA 200302722 B ZA200302722 B ZA 200302722B
- Authority
- ZA
- South Africa
- Prior art keywords
- ethyl
- alkyl
- amino
- phenyl
- halo
- Prior art date
Links
- 125000003118 aryl group Chemical group 0.000 title claims description 65
- 125000001072 heteroaryl group Chemical group 0.000 title description 4
- 239000000730 antalgic agent Substances 0.000 title description 2
- 150000002460 imidazoles Chemical class 0.000 title description 2
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 212
- -1 cyano, indanyl Chemical group 0.000 claims description 111
- 125000003545 alkoxy group Chemical group 0.000 claims description 96
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 90
- 125000002950 monocyclic group Chemical group 0.000 claims description 59
- 125000005843 halogen group Chemical group 0.000 claims description 56
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 229910052717 sulfur Inorganic materials 0.000 claims description 35
- 125000002619 bicyclic group Chemical group 0.000 claims description 34
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 32
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000005842 heteroatom Chemical group 0.000 claims description 31
- 125000002947 alkylene group Chemical group 0.000 claims description 30
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 29
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 28
- 125000003342 alkenyl group Chemical group 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 27
- 125000000304 alkynyl group Chemical group 0.000 claims description 25
- 125000004414 alkyl thio group Chemical group 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 11
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000005936 piperidyl group Chemical group 0.000 claims description 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 9
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims description 9
- 150000003180 prostaglandins Chemical class 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 125000004450 alkenylene group Chemical group 0.000 claims description 7
- 125000004419 alkynylene group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 3
- 239000002831 pharmacologic agent Substances 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 25
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 7
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 6
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 6
- VATAIZDYZPAXOX-UHFFFAOYSA-N (4-methylphenyl)sulfonylcarbamic acid Chemical compound CC1=CC=C(S(=O)(=O)NC(O)=O)C=C1 VATAIZDYZPAXOX-UHFFFAOYSA-N 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 4
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 3
- 239000005977 Ethylene Substances 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- OZTHHJWONRMDRZ-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-6-methoxybenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC=C(OC)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 OZTHHJWONRMDRZ-UHFFFAOYSA-N 0.000 claims 2
- ITZFODVISQIQFV-UHFFFAOYSA-N 1-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]propan-2-yl n-(4-methylphenyl)sulfonylcarbamate Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CC(C)OC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 ITZFODVISQIQFV-UHFFFAOYSA-N 0.000 claims 2
- QMHYCEZPVUGVHC-UHFFFAOYSA-N 2-[4-(2-butyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl n-(4-methylphenyl)sulfonylcarbamate Chemical compound CCCCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCOC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 QMHYCEZPVUGVHC-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- DJCKGBKRWDFMCI-UHFFFAOYSA-N 1-(1-benzothiophen-2-ylsulfonyl)-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound C1=CC=C2SC(S(=O)(=O)NC(=O)NCCC3=CC=C(C=C3)N3C4=NC(C)=CC(C)=C4N=C3CC)=CC2=C1 DJCKGBKRWDFMCI-UHFFFAOYSA-N 0.000 claims 1
- CMTOMNMETHIQAO-UHFFFAOYSA-N 1-(2-bromophenyl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=CC=C1Br CMTOMNMETHIQAO-UHFFFAOYSA-N 0.000 claims 1
- SSDHSAQPLKZVRY-UHFFFAOYSA-N 1-(2-chlorophenyl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=CC=C1Cl SSDHSAQPLKZVRY-UHFFFAOYSA-N 0.000 claims 1
- OJIFDBSNXCGHBQ-UHFFFAOYSA-N 1-(3-chlorophenyl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=CC(Cl)=C1 OJIFDBSNXCGHBQ-UHFFFAOYSA-N 0.000 claims 1
- XCVHOHHHDQCOBD-UHFFFAOYSA-N 1-(4-chloro-3-nitrophenyl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 XCVHOHHHDQCOBD-UHFFFAOYSA-N 0.000 claims 1
- FLDDGZZYHSLLJW-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(Cl)S1 FLDDGZZYHSLLJW-UHFFFAOYSA-N 0.000 claims 1
- DHQNPIRWIIQAKM-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,6-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(C)=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 DHQNPIRWIIQAKM-UHFFFAOYSA-N 0.000 claims 1
- UBBBCBCWMHKSKB-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-(4-phenylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C(C=C1)=CC=C1C1=CC=CC=C1 UBBBCBCWMHKSKB-UHFFFAOYSA-N 0.000 claims 1
- DCVOMGDWHZCNLH-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-naphthalen-1-ylsulfonylurea Chemical compound C1=CC=C2C(S(=O)(=O)NC(=O)NCCC3=CC=C(C=C3)N3C4=NC(C)=CC(C)=C4N=C3CC)=CC=CC2=C1 DCVOMGDWHZCNLH-UHFFFAOYSA-N 0.000 claims 1
- GPYDLTMRLWLKHM-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-naphthalen-2-ylsulfonylurea Chemical compound C1=CC=CC2=CC(S(=O)(=O)NC(=O)NCCC3=CC=C(C=C3)N3C4=NC(C)=CC(C)=C4N=C3CC)=CC=C21 GPYDLTMRLWLKHM-UHFFFAOYSA-N 0.000 claims 1
- GZFUZUFRJAEXPD-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]-3-thiophen-2-ylsulfonylurea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=CS1 GZFUZUFRJAEXPD-UHFFFAOYSA-N 0.000 claims 1
- CBFFANHNQPPLPD-UHFFFAOYSA-N 1-[2-[4-(5,6-dichloro-2-ethylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(Cl)=C(Cl)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 CBFFANHNQPPLPD-UHFFFAOYSA-N 0.000 claims 1
- YDZNQEMQWNXSGF-UHFFFAOYSA-N 1-[2-[4-(6-chloro-2-ethyl-5-methylsulfonylbenzimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(S(C)(=O)=O)=C(Cl)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 YDZNQEMQWNXSGF-UHFFFAOYSA-N 0.000 claims 1
- FIXXXBYFTUXZLG-UHFFFAOYSA-N 1-[2-[4-(6-ethyl-[1,3]dioxolo[4,5-f]benzimidazol-7-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC=3OCOC=3C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 FIXXXBYFTUXZLG-UHFFFAOYSA-N 0.000 claims 1
- GFMMZVFKQDQZHJ-UHFFFAOYSA-N 1-[2-[4-[2-ethyl-5-(2-hydroxypropan-2-yl)benzimidazol-1-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(C(C)(C)O)=CC=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 GFMMZVFKQDQZHJ-UHFFFAOYSA-N 0.000 claims 1
- ZVHXCMFIZUHPFN-UHFFFAOYSA-N 1-[2-[4-[5,7-dimethyl-2-(methylamino)imidazo[4,5-b]pyridin-3-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CNC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 ZVHXCMFIZUHPFN-UHFFFAOYSA-N 0.000 claims 1
- RWTZOYDKFYIGHY-UHFFFAOYSA-N 1-[2-[4-[6-chloro-2-(2-hydroxypropan-2-yl)-5-(trifluoromethyl)benzimidazol-1-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NCCC1=CC=C(N2C3=CC(Cl)=C(C=C3N=C2C(C)(C)O)C(F)(F)F)C=C1 RWTZOYDKFYIGHY-UHFFFAOYSA-N 0.000 claims 1
- NKJLJAMWLOQYMJ-UHFFFAOYSA-N 1-[3-(dihydroxyamino)phenyl]sulfonyl-3-[2-[4-(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)phenyl]ethyl]urea Chemical compound CCC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=CC(N(O)O)=C1 NKJLJAMWLOQYMJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 claims 1
- YNSMPQCCKLYELZ-UHFFFAOYSA-N 2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl n-(4-methylphenyl)sulfonylcarbamate Chemical compound CCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCOC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 YNSMPQCCKLYELZ-UHFFFAOYSA-N 0.000 claims 1
- JVMVTFXZGSJKKP-UHFFFAOYSA-N 2-[4-(4,6-dimethyl-2-phenylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl N-(4-methylphenyl)sulfonylcarbamate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)OCCC1=CC=C(N2C3=CC(C)=NC(C)=C3N=C2C=2C=CC=CC=2)C=C1 JVMVTFXZGSJKKP-UHFFFAOYSA-N 0.000 claims 1
- KTLAVEBBQHWJJN-UHFFFAOYSA-N 2-[4-(5-carbamoyl-6-chloro-2-ethylbenzimidazol-1-yl)phenyl]ethyl n-(4-methylphenyl)sulfonylcarbamate Chemical compound CCC1=NC2=CC(C(N)=O)=C(Cl)C=C2N1C(C=C1)=CC=C1CCOC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 KTLAVEBBQHWJJN-UHFFFAOYSA-N 0.000 claims 1
- RBSJXTXVNALVKT-UHFFFAOYSA-N 2-[4-[2-(2-acetamidopropan-2-yl)-6-chloro-5-(trifluoromethyl)benzimidazol-1-yl]phenyl]ethyl n-(4-methylphenyl)sulfonylcarbamate Chemical compound CC(=O)NC(C)(C)C1=NC2=CC(C(F)(F)F)=C(Cl)C=C2N1C(C=C1)=CC=C1CCOC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 RBSJXTXVNALVKT-UHFFFAOYSA-N 0.000 claims 1
- XLBNMEWNRBWUTH-UHFFFAOYSA-N 2-[4-[6-chloro-2-ethyl-5-(trifluoromethyl)benzimidazol-1-yl]phenyl]ethyl N-(5-chloro-1,3-dimethylpyrazol-4-yl)sulfonylcarbamate Chemical compound CCC1=NC2=CC(C(F)(F)F)=C(Cl)C=C2N1C(C=C1)=CC=C1CCOC(=O)NS(=O)(=O)C=1C(C)=NN(C)C=1Cl XLBNMEWNRBWUTH-UHFFFAOYSA-N 0.000 claims 1
- ZMJAHOBWGODFND-UHFFFAOYSA-N 2-[4-[6-chloro-2-ethyl-5-(trifluoromethyl)benzimidazol-1-yl]phenyl]ethyl N-(5-methylpyridin-2-yl)sulfonylcarbamate Chemical compound CCC1=NC2=CC(C(F)(F)F)=C(Cl)C=C2N1C(C=C1)=CC=C1CCOC(=O)NS(=O)(=O)C1=CC=C(C)C=N1 ZMJAHOBWGODFND-UHFFFAOYSA-N 0.000 claims 1
- RLOZEDWNVFSNCG-UHFFFAOYSA-N 2-[4-[6-chloro-2-ethyl-5-(trifluoromethyl)benzimidazol-1-yl]phenyl]ethyl n-(2-chlorophenyl)sulfonylcarbamate Chemical compound CCC1=NC2=CC(C(F)(F)F)=C(Cl)C=C2N1C(C=C1)=CC=C1CCOC(=O)NS(=O)(=O)C1=CC=CC=C1Cl RLOZEDWNVFSNCG-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 claims 1
- 101710127406 Glycoprotein 5 Proteins 0.000 claims 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 208000005171 Dysmenorrhea Diseases 0.000 description 6
- 206010013935 Dysmenorrhoea Diseases 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 206010049589 Afterbirth pain Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- 208000005024 Castleman disease Diseases 0.000 description 3
- 208000018380 Chemical injury Diseases 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000033131 Congenital factor II deficiency Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000031220 Hemophilia Diseases 0.000 description 3
- 208000009292 Hemophilia A Diseases 0.000 description 3
- 208000007646 Hypoprothrombinemias Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 201000002481 Myositis Diseases 0.000 description 3
- 206010028836 Neck pain Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 3
- 206010036600 Premature labour Diseases 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 208000010040 Sprains and Strains Diseases 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000015294 blood coagulation disease Diseases 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000009852 coagulant defect Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000007784 diverticulitis Diseases 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 230000010309 neoplastic transformation Effects 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 208000026440 premature labor Diseases 0.000 description 3
- 229940127293 prostanoid Drugs 0.000 description 3
- 150000003814 prostanoids Chemical class 0.000 description 3
- 201000007183 prothrombin deficiency Diseases 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 201000003068 rheumatic fever Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 230000016160 smooth muscle contraction Effects 0.000 description 3
- 201000004595 synovitis Diseases 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 229940122144 Prostaglandin receptor antagonist Drugs 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24182500P | 2000-10-19 | 2000-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200302722B true ZA200302722B (en) | 2004-04-08 |
Family
ID=22912331
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200302722A ZA200302722B (en) | 2000-10-19 | 2003-04-08 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents. |
| ZA200302991A ZA200302991B (en) | 2000-10-19 | 2003-04-16 | EP4 receptor inhibitors to treat rheumatoid arthritis. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200302991A ZA200302991B (en) | 2000-10-19 | 2003-04-16 | EP4 receptor inhibitors to treat rheumatoid arthritis. |
Country Status (49)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7544511B2 (en) * | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
| ATE402164T1 (de) * | 2001-04-26 | 2008-08-15 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| EP1494667A1 (en) | 2002-04-12 | 2005-01-12 | Pfizer Japan Inc. | Imidazole compounds as anti-inflammatory and analgesic agents |
| JP2005532291A (ja) | 2002-04-12 | 2005-10-27 | ファイザー株式会社 | 抗炎症薬および鎮痛薬としてのピラゾール化合物 |
| CN101023946A (zh) * | 2002-04-12 | 2007-08-29 | 美国辉瑞有限公司 | Ep4受体配体在治疗il－6相关疾病的应用 |
| US8293488B2 (en) | 2002-12-09 | 2012-10-23 | Neuralstem, Inc. | Method for screening neurogenic agents |
| WO2004053071A2 (en) * | 2002-12-09 | 2004-06-24 | Judith Kelleher-Andersson | Method for discovering neurogenic agents |
| ATE368456T1 (de) * | 2002-12-20 | 2007-08-15 | Dynogen Pharmaceuticals Inc | Behandlung nicht-schmerzhafter blasenstörungen mit modulatoren von alpha-2-delta- calciumkanaluntereinheiten |
| JP4631702B2 (ja) * | 2003-02-14 | 2011-02-16 | 和光純薬工業株式会社 | イオン交換樹脂固定化白金触媒を用いたヒドロキシルアミン化合物の製造方法 |
| CN101503393B (zh) * | 2003-03-13 | 2015-08-19 | 出光兴产株式会社 | 含氮杂环衍生物及使用该衍生物的有机电致发光元件 |
| US20070105931A1 (en) * | 2003-08-04 | 2007-05-10 | Mayo Foundation For Medical Education And Research | Methods and compositions for inhibiting the proliferation of prostate cancer cells |
| FR2860514A1 (fr) | 2003-10-03 | 2005-04-08 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| EP1700129B1 (en) * | 2003-12-23 | 2007-11-28 | Roche Diagnostics GmbH | Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6 |
| BRPI0509993A (pt) * | 2004-04-20 | 2007-10-16 | Pfizer Prod Inc | combinações compreendendo ligandos de alfa-2-delta |
| US7271271B2 (en) * | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
| ES2537004T3 (es) * | 2004-11-17 | 2015-06-01 | Neuralstem, Inc. | Trasplante de células neurales humanas para el tratamiento de afecciones neurodegenerativas |
| CN101119973B (zh) * | 2004-12-17 | 2011-08-03 | 默克弗罗斯特加拿大有限公司 | 作为mPGES-1抑制剂的2-(苯基或者杂环基)-1H-菲并[9,10-d]咪唑类化合物 |
| US7442716B2 (en) * | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
| KR100911073B1 (ko) * | 2005-03-11 | 2009-08-06 | 라퀄리아 파마 인코포레이티드 | 이미다졸 유도체의 결정 형태 |
| EP1963276B9 (en) * | 2005-12-21 | 2012-09-26 | Decode Genetics EHF | N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation |
| US20090192158A1 (en) * | 2006-05-02 | 2009-07-30 | Stacia Kargman | Methods for Treating or Preventing Neoplasias |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| AU2008232265B2 (en) * | 2007-03-26 | 2013-02-28 | Merck Canada Inc. | Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists |
| DE102007037579B4 (de) | 2007-08-09 | 2012-05-16 | Emc Microcollections Gmbh | Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe |
| ES2424214T3 (es) * | 2007-08-27 | 2013-09-30 | Siga Technologies, Inc. | Medicamentos antivirales para el tratamiento de una infección por Arenavirus |
| WO2009093026A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
| CN102224154A (zh) * | 2008-09-25 | 2011-10-19 | 默克弗罗斯特加拿大有限公司 | 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物 |
| WO2010087425A1 (ja) | 2009-01-30 | 2010-08-05 | 国立大学法人京都大学 | 前立腺癌の進行抑制剤および進行抑制方法 |
| CN102421429B (zh) | 2009-04-22 | 2016-08-17 | 拉夸里亚创药株式会社 | 癌症治疗用选择性ep4受体拮抗物质 |
| KR101041561B1 (ko) * | 2009-12-21 | 2011-06-15 | 짚라인코리아 (주) | 비행용 착용복 |
| CA2789665C (en) * | 2010-02-22 | 2020-06-16 | Raqualia Pharma Inc. | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
| US9540611B2 (en) | 2010-07-28 | 2017-01-10 | Neuralstem, Inc. | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
| HUE031408T2 (en) | 2010-09-21 | 2017-07-28 | Eisai R&D Man Co Ltd | Pharmaceutical preparation |
| EP2669271A4 (en) * | 2011-01-25 | 2014-08-13 | Kissei Pharmaceutical | INDOLE DERIVATIVE AND PHARMACEUTICAL ACCEPTABLE SALT THEREOF |
| TW201326154A (zh) * | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| BR112015023663A2 (pt) * | 2013-03-19 | 2020-10-20 | Askat Inc. | uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável deste, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb) ou um sal farmaceuticamente aceitável deste, composição farmacêutica para o tratamento de doença de cartilagem, método para o tratamento de doenças de cartilagem em um indivíduo animal, incluindo um indivíduo mamífero e composto da fórmula (i), (ii),(iii), (iv), (va) ou (vb) ou um sal farmaceuticamente aceitável deste |
| WO2014153280A1 (en) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP3040329B1 (en) * | 2013-08-29 | 2018-10-10 | Kyoto Pharmaceutical Industries, Ltd. | Aromatic compound and use thereof in the treatment of disorders associated with bone metabolism |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| CA2941008C (en) * | 2014-03-06 | 2022-07-26 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| PT3295941T (pt) | 2014-03-06 | 2020-08-25 | Aratana Therapeutics Inc | Processo para preparar a forma a do grapiprant |
| MX2017005186A (es) | 2014-10-20 | 2017-07-26 | Neuralstem Inc | Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas. |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| CN105486851A (zh) * | 2015-11-20 | 2016-04-13 | 中国药科大学 | 一种基于荧光共振能量转移技术的前列腺素受体4筛选模型 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| AU2018207402B2 (en) | 2017-01-11 | 2023-09-28 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| WO2018162562A1 (en) | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| US11446298B2 (en) | 2017-05-18 | 2022-09-20 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| DK3625224T3 (da) | 2017-05-18 | 2021-11-08 | Idorsia Pharmaceuticals Ltd | N-substituerede indolderivater |
| KR102612649B1 (ko) | 2017-05-18 | 2023-12-11 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 벤조푸란 및 벤조티오페논 유도체 |
| UA125123C2 (uk) | 2017-05-18 | 2022-01-12 | Ідорсія Фармасьютікалз Лтд | Фенільні похідні як модулятори pge2 рецепторів |
| WO2018210988A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
| EP3664802B1 (en) | 2017-08-07 | 2022-02-23 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| RU2659169C1 (ru) * | 2017-10-31 | 2018-06-28 | Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" | Способ прогнозирования риска развития иммуноопосредованных заболеваний у работающих в условиях обсеменённости воздуха рабочей зоны условно-патогенными микроорганизмами |
| CA3096546A1 (en) * | 2018-04-16 | 2019-10-24 | Arrys Therapeutics, Inc. | Ep4 inhibitors and use thereof |
| US10239885B1 (en) | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
| WO2020014445A1 (en) * | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Ep4 inhibitors and synthesis thereof |
| US20210315909A1 (en) * | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| FI3860998T3 (fi) | 2018-10-05 | 2024-03-27 | Annapurna Bio Inc | Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon |
| WO2020160074A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Synthetic process and novel intermediates |
| EP3917932A4 (en) | 2019-01-30 | 2022-09-28 | Avista Pharma Solutions, Inc. | CHEMICAL COMPOUNDS |
| WO2021027722A1 (zh) * | 2019-08-09 | 2021-02-18 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| US11254675B2 (en) | 2019-08-12 | 2022-02-22 | Cadila Healthcare Limited | Process for preparation of grapiprant |
| WO2021226162A1 (en) | 2020-05-05 | 2021-11-11 | Arrys Therapeutics, Inc. | Ep4 antagonists and their use in the treatment of proliferative diseases |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| CN116478155A (zh) * | 2022-01-17 | 2023-07-25 | 洛阳惠中兽药有限公司 | 一种格拉匹伦及其中间体的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8804439D0 (en) * | 1988-02-25 | 1988-03-23 | Pfizer Ltd | Dihydropyridines |
| IL94805A (en) | 1989-06-28 | 1994-04-12 | Ciba Geigy Ag | Certain translocated carboxylic acids (a) Arylsulfonamide - and pyridyl - or imidazolil (), process for their preparation and pharmaceutical preparations containing them |
| GB9009469D0 (en) * | 1990-04-27 | 1990-06-20 | British Bio Technology | Compounds |
| GB9010404D0 (en) * | 1990-05-09 | 1990-06-27 | Pfizer Ltd | Therapeutic agents |
| GB2330307A (en) * | 1998-02-07 | 1999-04-21 | Glaxo Group Ltd | EP4 Receptor antagonists as bone resorption inhibitors |
| WO1999047497A2 (en) * | 1998-03-13 | 1999-09-23 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| AU6427599A (en) | 1998-10-15 | 2000-05-01 | Merck & Co., Inc. | Methods for stimulating bone formation |
| CA2346038A1 (en) * | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
| JP2000191615A (ja) * | 1998-10-20 | 2000-07-11 | Takeda Chem Ind Ltd | 芳香族アミン誘導体、その製造法および剤 |
| JP2002543067A (ja) | 1999-04-22 | 2002-12-17 | シナプティック・ファーマスーティカル・コーポレーション | 選択的なｎｐｙ（ｙ５）のアンタゴニスト |
| JP4598278B2 (ja) | 1999-04-28 | 2010-12-15 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｐｐａｒ受容体リガンドとしてのジアリール酸誘導体 |
| GB0031315D0 (en) | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Indole derivatives |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
-
2001
- 2001-10-08 HN HN2001000224A patent/HN2001000224A/es unknown
- 2001-10-15 CA CA002426487A patent/CA2426487A1/en not_active Abandoned
- 2001-10-15 AU AU2002210796A patent/AU2002210796B8/en not_active Ceased
- 2001-10-15 AT AT01978702T patent/ATE320428T1/de not_active IP Right Cessation
- 2001-10-15 EP EP06110920.3A patent/EP1666480B1/en not_active Expired - Lifetime
- 2001-10-15 EP EP01974609A patent/EP1326606A2/en not_active Withdrawn
- 2001-10-15 OA OA1200300110A patent/OA12523A/en unknown
- 2001-10-15 CZ CZ2003979A patent/CZ2003979A3/cs unknown
- 2001-10-15 SK SK460-2003A patent/SK4602003A3/sk not_active Application Discontinuation
- 2001-10-15 EE EEP200300188A patent/EE200300188A/xx unknown
- 2001-10-15 KR KR1020037005443A patent/KR100582319B1/ko active IP Right Grant
- 2001-10-15 CN CNA018199763A patent/CN1477960A/zh active Pending
- 2001-10-15 PL PL01365781A patent/PL365781A1/xx not_active Application Discontinuation
- 2001-10-15 AU AU2001294122A patent/AU2001294122A1/en not_active Abandoned
- 2001-10-15 JP JP2002536282A patent/JP4060182B2/ja not_active Expired - Lifetime
- 2001-10-15 ES ES01978702T patent/ES2258554T3/es not_active Expired - Lifetime
- 2001-10-15 GE GE5160A patent/GEP20053673B/en unknown
- 2001-10-15 NZ NZ525163A patent/NZ525163A/en unknown
- 2001-10-15 BR BRPI0114704A patent/BRPI0114704B8/pt not_active IP Right Cessation
- 2001-10-15 DE DE60118020T patent/DE60118020T2/de not_active Expired - Lifetime
- 2001-10-15 OA OA1200300117A patent/OA12526A/en unknown
- 2001-10-15 SK SK443-2003A patent/SK4432003A3/sk not_active Application Discontinuation
- 2001-10-15 DZ DZ013513A patent/DZ3513A1/fr active
- 2001-10-15 ES ES06110920.3T patent/ES2524586T3/es not_active Expired - Lifetime
- 2001-10-15 YU YU31303A patent/YU31303A/sh unknown
- 2001-10-15 CN CN201010279474.6A patent/CN101967146B/zh not_active Expired - Lifetime
- 2001-10-15 EA EA200300387A patent/EA200300387A1/ru unknown
- 2001-10-15 EP EP01978702A patent/EP1326864B1/en not_active Expired - Lifetime
- 2001-10-15 SI SI200130519T patent/SI1326864T1/sl unknown
- 2001-10-15 AP APAP/P/2001/002299A patent/AP2001002299A0/en unknown
- 2001-10-15 KR KR10-2003-7005477A patent/KR20030048060A/ko not_active Application Discontinuation
- 2001-10-15 EE EEP200300190A patent/EE200300190A/xx unknown
- 2001-10-15 US US09/977,621 patent/US6710054B2/en not_active Expired - Lifetime
- 2001-10-15 WO PCT/IB2001/001942 patent/WO2002032422A2/en not_active Application Discontinuation
- 2001-10-15 US US09/977,761 patent/US20020077329A1/en not_active Abandoned
- 2001-10-15 PT PT01978702T patent/PT1326864E/pt unknown
- 2001-10-15 WO PCT/IB2001/001940 patent/WO2002032900A2/en active Application Filing
- 2001-10-15 PL PL01362171A patent/PL362171A1/xx not_active Application Discontinuation
- 2001-10-15 UA UA2003043568A patent/UA74391C2/uk unknown
- 2001-10-15 MX MXPA03003448A patent/MXPA03003448A/es unknown
- 2001-10-15 DK DK01978702T patent/DK1326864T3/da active
- 2001-10-15 EA EA200300391A patent/EA005991B1/ru not_active IP Right Cessation
- 2001-10-15 HU HU0600593A patent/HUP0600593A3/hu unknown
- 2001-10-15 HU HU0303766A patent/HUP0303766A3/hu unknown
- 2001-10-15 CA CA002426457A patent/CA2426457C/en not_active Expired - Lifetime
- 2001-10-15 MX MXPA03003463A patent/MXPA03003463A/es active IP Right Grant
- 2001-10-15 CN CNA018192858A patent/CN1476448A/zh active Pending
- 2001-10-15 AU AU1079602A patent/AU1079602A/xx active Pending
- 2001-10-15 JP JP2002535660A patent/JP2004511518A/ja not_active Withdrawn
- 2001-10-15 CZ CZ20031010A patent/CZ20031010A3/cs unknown
- 2001-10-15 BR BR0114758-7A patent/BR0114758A/pt not_active IP Right Cessation
- 2001-10-15 IL IL15543901A patent/IL155439A0/xx unknown
- 2001-10-15 AP APAP/P/2003/002806A patent/AP2003002806A0/en unknown
- 2001-10-15 IL IL15543801A patent/IL155438A0/xx unknown
- 2001-10-17 PE PE2001001031A patent/PE20020548A1/es not_active Application Discontinuation
- 2001-10-17 AR ARP010104879A patent/AR035498A1/es not_active Application Discontinuation
- 2001-10-18 TN TNTNSN01145A patent/TNSN01145A1/fr unknown
- 2001-10-18 TW TW095141488A patent/TW200716100A/zh unknown
- 2001-10-18 SV SV2001000696A patent/SV2002000696A/es unknown
- 2001-10-18 TW TW090125805A patent/TWI294424B/zh active
- 2001-10-19 PA PA20018531001A patent/PA8531001A1/es unknown
- 2001-10-19 GT GT200100211A patent/GT200100211A/es unknown
- 2001-10-19 UY UY26977A patent/UY26977A1/es not_active Application Discontinuation
- 2001-10-19 GT GT200100211AK patent/GT200100211AA/es unknown
- 2001-11-18 DO DO2001000271A patent/DOP2001000271A/es unknown
-
2003
- 2003-03-31 IS IS6765A patent/IS6765A/is unknown
- 2003-04-03 BG BG107699A patent/BG107699A/bg unknown
- 2003-04-04 CR CR6951A patent/CR6951A/es not_active Application Discontinuation
- 2003-04-08 MA MA27097A patent/MA26952A1/fr unknown
- 2003-04-08 ZA ZA200302722A patent/ZA200302722B/en unknown
- 2003-04-08 NO NO20031582A patent/NO20031582L/no not_active Application Discontinuation
- 2003-04-09 HR HR20030269A patent/HRP20030269A2/hr not_active Application Discontinuation
- 2003-04-10 NO NO20031658A patent/NO20031658L/no not_active Application Discontinuation
- 2003-04-10 CR CR6955A patent/CR6955A/es not_active Application Discontinuation
- 2003-04-14 IS IS6785A patent/IS6785A/is unknown
- 2003-04-15 MA MA27107A patent/MA26955A1/fr unknown
- 2003-04-16 BG BG107732A patent/BG107732A/bg unknown
- 2003-04-16 ZA ZA200302991A patent/ZA200302991B/en unknown
- 2003-04-16 EC EC2003004563A patent/ECSP034563A/es unknown
- 2003-04-24 EC EC2003004569A patent/ECSP034569A/es unknown
-
2004
- 2004-02-04 US US10/771,696 patent/US7141580B2/en not_active Expired - Lifetime
-
2006
- 2006-03-30 CY CY20061100447T patent/CY1105035T1/el unknown
- 2006-11-03 US US11/556,523 patent/US7479564B2/en not_active Expired - Lifetime
-
2007
- 2007-06-11 JP JP2007154590A patent/JP4703607B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200302722B (en) | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents. | |
| AU2009319048B2 (en) | Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor | |
| RU2285527C2 (ru) | Использование лигандов рецептора ер4 для лечения опосредованных il-6 заболеваний | |
| AU2002210796A1 (en) | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | |
| KR20090010112A (ko) | Ｍｔｏｒ 억제제 및 ｒａｆ 키나제 억제제를 포함하는 약학적 조합물 | |
| AU2014200357A1 (en) | Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor |